BL0006 not checked

Shanghai Best-Link Bioscience, LLC

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.”In the company’s words, NCT06247657 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor
Main trialPhase 1
“This is the first in human study of BL0006, and the primary objective is to evaluate the safety and tolerability of BL0006 as a single agent in patients with advanced solid tumors.”In the company’s words, NCT06247657 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumor

All 2440 drugs for Advanced Solid Tumor

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Unknown Oct 2024 A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BL0006

Following is part of Solo: you see every change to BL0006 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in